Relevant bibliographies by topics / Blinatumomab

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Blinatumomab'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Blinatumomab.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Blinatumomab"

1

&NA;. "Blinatumomab." Reactions Weekly &NA;, no. 1339 (2011): 12. http://dx.doi.org/10.2165/00128415-201113390-00033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Buie, Larry W., Joshua J. Pecoraro, Troy Z. Horvat, and Ryan J. Daley. "Blinatumomab." Annals of Pharmacotherapy 49, no. 9 (2015): 1057–67. http://dx.doi.org/10.1177/1060028015588555.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chen, Yun-Hsiang, Yun Wang, Cheng-Hao Liao та Shu-Ching Hsu. "The potential of adoptive transfer of γ9δ2 T cells to enhance blinatumomab’s antitumor activity against B-cell malignancy". Scientific Reports 11, № 1 (2021). http://dx.doi.org/10.1038/s41598-021-91784-1.

Full text
Abstract:
AbstractBlinatumomab, a bispecific T cell engager (BiTE) antibody targeting CD19 and CD3ε, can redirect T cells toward CD19-positive tumor cells and has been approved to treat relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). However, chemotherapeutic regimens can severely reduce T cells’ number and cytotoxic function, leading to an inadequate response to blinatumomab treatment in patients. In addition, it was reported that a substantial portion of R/R B-ALL patients failing blinatumomab treatment had the extramedullary disease, indicating the poor ability of blinatumomab in
APA, Harvard, Vancouver, ISO, and other styles
4

"Blinatumomab." Reactions Weekly 1854, no. 1 (2021): 87. http://dx.doi.org/10.1007/s40278-021-95418-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Blinatumomab." Reactions Weekly 1840, no. 1 (2021): 91. http://dx.doi.org/10.1007/s40278-021-90234-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Blinatumomab." Reactions Weekly 1837, no. 1 (2021): 115. http://dx.doi.org/10.1007/s40278-021-88714-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Blinatumomab." Reactions Weekly 1843, no. 1 (2021): 82. http://dx.doi.org/10.1007/s40278-021-91184-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Blinatumomab." Reactions Weekly 1847, no. 1 (2021): 101. http://dx.doi.org/10.1007/s40278-021-92658-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"Blinatumomab." Reactions Weekly 1846, no. 1 (2021): 64. http://dx.doi.org/10.1007/s40278-021-92312-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"Blinatumomab." Reactions Weekly 1925, no. 1 (2022): 131. http://dx.doi.org/10.1007/s40278-022-23908-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Blinatumomab"

1

Volpato, Francesca <1986&gt. "L'utilizzo clinico del blinatumomab nella terapia della leucemia linfoblastica acuta: l'esperienza di Bologna." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2018. http://amsdottorato.unibo.it/8651/1/tesi%20FINALE%20RISULTATI.pdf.

Full text
Abstract:
La leucemia acuta linfoblastica a cellule B è una patologia rara nell'adulto (insorgenza pari a 1.1/100.000 abitanti) caratterizzata da una pessima prognosi. Risulta definita da tassi di sopravvivenza globale a 5 anni che nonostante gli sviluppi terapeutici negli ultimi due decenni non sono incrementati, con valori di sopravvivenza media del 49% nei pazienti standard-risk e del 24% nei pazienti high-risk. L'utilizzo di anticorpi ingegnerizzati bispecifici BiTE sembra dare risultati promettenti nei pazienti con neoplasie ematologiche. Nel nostro centro sono stati avviati tre protocolli di trat
APA, Harvard, Vancouver, ISO, and other styles
2

Dufner, Vera Christine Verfasser], Ralf C. [Gutachter] [Bargou, Götz [Gutachter] Gelbrich, Peter [Gutachter] Heuschmann, and Maria-Elisabeth [Gutachter] Göbeler. "Effektivität und Sicherheit von Blinatumomab im Long-term Follow-up bei Non-Hodgkin-Lymphom-Patienten / Vera Christine Dufner ; Gutachter: Ralf Bargou, Götz Gelbrich, Peter Heuschmann, Maria-Elisabeth Göbeler." Würzburg : Universität Würzburg, 2020. http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-184762.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dufner, Vera Christine [Verfasser], Ralf [Gutachter] Bargou, Götz [Gutachter] Gelbrich, Peter [Gutachter] Heuschmann, and Maria-Elisabeth [Gutachter] Göbeler. "Effektivität und Sicherheit von Blinatumomab im Long-term Follow-up bei Non-Hodgkin-Lymphom-Patienten / Vera Christine Dufner ; Gutachter: Ralf Bargou, Götz Gelbrich, Peter Heuschmann, Maria-Elisabeth Göbeler." Würzburg : Universität Würzburg, 2020. http://d-nb.info/1210426390/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dufner, Vera Christine. "Effektivität und Sicherheit von Blinatumomab im Long-term Follow-up bei Non-Hodgkin-Lymphom-Patienten." Doctoral thesis, 2020. https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-184762.

Full text
Abstract:
Das Non-Hodgkin-Lymphom (NHL) steht an siebter Stelle der Inzidenzen aller Krebserkrankungen, mit jährlich steigender Tendenz. Wie kann einer so gefährlichen und heterogenen Krankheitsentität in der heutigen Medizin angemessen begegnet werden? Neben etablierten Therapien, die geraden bei rezidivierten oder refraktären NHL an ihre Grenzen stoßen, bieten experimentelle Therapieansätze neue Hoffnung: Blinatumomab ist ein bispezifischer Antikörper, der durch seine beiden Domänen als Adapter für die T-Zelle und die Tumor-Zelle fungiert und eine Zytolyse der malignen B-Zelle induziert. Bei der ALL f
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Blinatumomab"

1

Hodgkiss, Andrew. Psychiatric consequences of cancer treatments: therapeutic monoclonal antibodies. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198759911.003.0009.

Full text
Abstract:
The adverse psychiatric consequences of a range of monoclonal antibodies used to treat cancer are reviewed. Bevacizumab disrupts endothelial function at the blood–brain barrier and can provoke posterior reversible encephalopathy syndrome. The immune checkpoint inhibitors cause autoimmune hypophysitis and thyroiditis with associated psychopathology. Rituximab causes profound immunosuppression of B lymphocytes, and hence can reactivate childhood JC virus infection to cause progressive multifocal leucoencephalopathy. The marked neuropsychiatric toxicity of blinatumomab is described.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Blinatumomab"

1

Stelljes, Matthias, David I. Marks, and Sebastian Giebel. "Acute Lymphoblastic Leukemia in Adults." In The EBMT Handbook. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-44080-9_72.

Full text
Abstract:
AbstractThe prognosis of patients with acute lymphoblastic leukemia is constantly improving. Beside optimization strategies of conventional chemotherapies and close monitoring of treatment response (e.g. by PCR-based measurement of measurable disease, which helps to early identify patients at risk for relapse), the integration of antibody (e.g. anti-CD20)/antibody-based drugs (blinatumomab and inotuzumab-ozogamicin) to frontline and/or salvage therapy protocols led to significant improvements. However, allogeneic HCT still plays a fundamental role in the treatment of high-risk patients in 1st
APA, Harvard, Vancouver, ISO, and other styles
2

Takada, Satoru. "Blinatumomab for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results." In Chemotherapy for Leukemia. Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-3332-2_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Baeuerle, Patrick A. "Development of T-Cell-Engaging Bispecific Antibody Blinatumomab (Blincyto®) for Treatment of B-Cell Malignancies." In Successful Drug Discovery. Wiley-VCH Verlag GmbH & Co. KGaA, 2018. http://dx.doi.org/10.1002/9783527808694.ch5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Simpson, Michelle C., and Eric G. Schaefer. "Blinatumomab." In Extended Stability for Parenteral Drugs. ASHP, 2022. http://dx.doi.org/10.37573/9781585286720.022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Blinatumomab." In Extended Stability for Parenteral Drugs. American Society of Health-System Pharmacists, 2017. http://dx.doi.org/10.37573/9781585285280.019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Blinatumomab." In ASHP® Injectable Drug Information™. ASHP, 2021. http://dx.doi.org/10.37573/9781585286850.054.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Phelps, Stephanie J., Tracy M. Hagemann, and Kelley R. Lee. "Blinatumomab." In Pediatric Injectable Drugs. ASHP, 2024. http://dx.doi.org/10.37573/9781585287192.041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Blinatumomab." In ASHP® Injectable Drug Information™. ASHP, 2024. https://doi.org/10.37573/9781585287444.055.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Blinatumomab"

1

van den Heuvel, Robert. "Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL." In 64th ASH Annual Meeting, edited by Gert Ossenkoppele. Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/50f6de65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

van den Heuvel, Robert. "Blinatumomab may improve outcomes in patients with B-cell ALL undergoing ASCT." In EBMT Annual Meeting 2023, edited by Prof Gert Ossenkoppele. Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/692c5ed7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hizal, Mina, Deniz Yaşar, Tuğba Ramaslı Gürsoy, Şule Yeşil, and Ali Fettah. "Blinatumomab-Induced Pneumonitis in a Pediatric Case in B-cell Acute Lymphoblastic Leukemia." In ERS Congress 2024 abstracts. European Respiratory Society, 2024. http://dx.doi.org/10.1183/13993003.congress-2024.pa551.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

van den Heuvel, Robert. "Blinatumomab reduces toxicity in the consolidation phase in paediatric high-risk B-cell ALL." In 65th ASH Annual Meeting, edited by Gert Ossenkoppele. Medicom Medical Publishers, 2024. http://dx.doi.org/10.55788/19866a5c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dubke, J., B. Schattling, I. A. Bley, M. Klokow, I. Müller та M. Queudeville. "γ/δ-T cells for the immunotherapy of pediatric acute lymphoblastic leukemia with blinatumomab". У 35. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch onkologische Forschung. Georg Thieme Verlag KG, 2024. http://dx.doi.org/10.1055/s-0044-1786568.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lazaro, J., C. Alcon, A. Lissat, J. Montero, and C. Eckert. "Exploring Synergistic Approaches to Enhance Blinatumomab&apos;s Efficacy in Acute Lymphoblastic Leukemia." In 35. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch onkologische Forschung. Georg Thieme Verlag KG, 2024. http://dx.doi.org/10.1055/s-0044-1786596.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hassani, L., N. Osman, S. Nguyen, et al. "PP-036 Blinatumomab: organisational and economic optimisation of treatment and proposal for scheduled patient care." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.483.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Qiang, Xiangnan, Ronghua Zhang, Zhixiang Zhang, et al. "294 Comparison of preclinical efficacy between CD19 CAR-T and CD3×CD19 bispecific antibody (blinatumomab)." In SITC 38th Annual Meeting (SITC 2023) Abstracts. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/jitc-2023-sitc2023.0294.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Repaire, T. du, P. Vigne, A. Savry, L. Gauthier-Villano, B. Pourroy, and P. Bertault-Peres. "CP-172 Visual compatibility of BLINATUMOMAB with selected co-administrated drugs during simulated y site administration." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.170.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Radichev, Ilian, Jiwon Yang, Won Lee, Destanie Rose, and James G. Keck. "1259 Comparison of blinatumomab and biosimilar CD19xCD3 BiTE responses in PBMC-humanized mice used as a preclinical lymphoma mouse model." In SITC 38th Annual Meeting (SITC 2023) Abstracts. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/jitc-2023-sitc2023.1259.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Blinatumomab' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography